Controlling the genotoxins ethyl chloride and methyl chloride formed during the preparation of amine hydrochloride salts from solutions of ethanol and methanol

Organic Process Research and Development

Volumn 13, Issue 4, 2009, Pages 786-791

  Yang, Qiang ^a   Haney, Brian P ^a   Vaux, Alexander ^a   Riley, Dean A ^a,b   Heidrich, Linda ^a   He, Ping ^a   Mason, Paul ^a   Ashok Tehim, ^c   Fisher, Lawrence E ^d   Maag, Hans ^d   Anderson, Neal G ^e  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

^b SAFC Pharma ^*  (United Kingdom)

^c Memory Pharmaceuticals Corporation   (United States)

^d ROCHE BIOSCIENCE   (United States)

^e Anderson s Process Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68349133339     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op9000737     Document Type: Article

References (42)

1. Robinson, D. Regulatory Highlights for January to August 2007. Org. Process Res. Dev. 2007, 11, 797.
2. Robinson, D. Regulatory Highlights for 2006 to March 2007. Org. Process Res. Dev. 2007, 11, 311.
3. Pierson, D. A.; Olsen, B. A.; Robbins, D. K.; Devries, K. M.; Varie, D. L. Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances. Org. Process Res. Dev. 2009, 13, 285.
4. Laird, T. Dangers of the Unknown. Org. Process Res. Dev. 2003, 7, 225.
5. Delaney, E. J. An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals. Regul. Toxicol. Pharmacol. 2007, 49 (2), 107.
6. Humfrey, C. D. N. Recent Developments in the Risk Assessment of Potentially Genotoxic Impurities in Pharmaceutical Drug Substances. Toxicol. Sci. 2007, 100 (1), 24.
7. Bouder, F. Regulating impurities in pharmaceutical products: a tolerability of risk approach? Expert Rev. Clin. Pharmacol. 2008, 1, 241.
8. Elder, D. P.; Teasdale, A.; Lipczynski, A. M. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs). J.Pharm. Biomed. Anal. 2008, 46, 1.
9. Kruhlak, N. L.; Contrera, J. F.; Benz, R. D.; Matthews, E. J. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. AdV. Drug Delivery Rev. 2007, 59, 43.
10. Snodin, D. J. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: Real or imaginary problems? Regul. Toxicol. Pharmacol. 2006, 45, 79.
11. The Carcinogenic Potency Database, For databases, see, National Toxicology Program Report on Carcinogens, http://ntp.niehs.nih.gov/index.cfm? objectid)72016262-BDB7-CEBA-FA60E922B18C2540 (accessed March 29, 2009).
12. Jacobson-Kram, D.; McGovern, T. Toxicological overview of impurities in pharmaceutical products. AdV. Drug Delivery Rev. 2007, 59, 38.
13. Mayer, J.; Cheeseman, M. A.; Twaroski, M. L. Structure-activity relationship analysis tools: Validation and applicability in predicting carcinogens. Regul. Toxicol. Pharmacol. 2007, 50 (1), 50.
14. European Medicines Evaluation Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02, June 28, 2006 London. http://www.emea.europa.eu/pdfs/human/ swp/519902en.pdf (accessed March 29, 2009).
15. Argentine, M. D.; Owens, P. K.; Olsen, B. A. Strategies for the investigation and control of process-related impurities in drug substances. AdV. Drug Delivery Rev. 2007, 59, 12.
16. Müller, L.; Mauthe, R. J.; Riley, C. M.; Andino, M. M.; De Antonis, D.; Beels, C.; DeGeorge, J.; De Knaep, A. G. M.; Ellison, D.; Fagerland, J. A.; Frank, R.; Fritschel, B.; Galloway, S.; Harpur, E.; Humfrey, C. D. N.; Jacks, A. S.; Jagota, N.; Mackinnon, J.; Mohan, G.; Ness, D. K.; O-Donovan, M. R.; Smith, M. D.; Vudathala, G.; Yotti, L. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 2006, 44 (3), 198.
17. http://www.nytimes.com/2007/07/23/health/23recall.html?-r)1&scp) 1&sq)viracept&st)cse (accessed March 29, 2009).
18. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viracept/Viracept- H-164-Z-109-AR.pdf (accessed March 29, 2009).
19. http://www.emea.europa.eu/Inspections/docs/4471408en.pdf (accessed March 29, 2009).
20. Prior to the discovery of batches of nelfinavir mesylate that were contaminated with ethyl mesylate, toxicological data were not available to establish a threshold dose response for ethyl mesylate. Roche subsequently conducted extensive toxicological studies on ethyl mesylate, and on the basis of these data calculated that the permitted threshold dosage in humans was 370 times higher than the highest level of ethyl mesylate found in those batches of nelfinavir mesylate: http://www.roche-hiv.com/portal/eipf/pb/hiv/Roche-HIV/2008? paf-pageId)re7283195&paf-gear-id)20000003&paf-dm)full&faq-mode) detailed&doc-id)re7300002/re71700003/re73300004/re731001/faq/FAQ-00983. headline (accessed March 29, 2009); http://www.aids2008.org/Pag/Abstracts.aspx? AID)16184 (accessed March 29, 2009)
21. After reviewing the toxicological data, the EMEA concluded that monitoring patients that had been inadvertently exposed to high levels of ethyl mesylate in these batches of nelfinavir mesylate was not necessary. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viracept/38225608en.pdf (accessed March 29, 2009).
22. Acetamide is non-mutagenic (negative in Ames assay) and thus is not a genotoxin. The International Agency for Research on Cancer (IARC) has classified acetamide as possibly carcinogenic to humans (Group 2B) based on rodent toxicity data and thus is controlled to a threshold level of ≤5 μg/day,http://www.inchem.org/documents/iarc/vol71/053-acetamide.html (accessed May 5,2008)
23. According to the FDA-s EAFUS (Everything Added to Food in the U.S.) database (http://vm.cfsan.fda.gov/«dms/eafus.html), "The EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food additives or listed or affirmed as GRAS (Generally Recognized as Safe)." In this table acetamide is listed in the EAF category, meaning "There is reported use of the substance, but it has not yet been assigned for toxicology literature search." (Accessed May 19, 2008)
24. The Flavor and Extracts Manufacturers Association Expert Panel, an independent organization, has included acetamide in the GRAS (Generally Recognized as Safe) list, with the average maximum use level of 5 ppm for baked goods. http://members.ift.org/NR/rdonlyres/B9066605-9760-4E67-82BA-B2AA8D343020/ 0/0805gras22-complete.pdf (accessed 5/20/08).
25. Anderson, N. G. Personal communication.
26. Jacobson-Kram, D.; Jacobs, A. Use of Genotoxicity Data to Support Clinical Trials or Positive Genetox Findings on a Candidate Pharmaceutical or Impurity....Now What? Int. J. Toxicol. 2005, 24, 129
27. McGovern, T.; Jacobson-Kram, D. Regulation of genotoxic and carcinogenic impurities in drug substances and products. Trends Anal. Chem. 2006, 25, 790.
28. For instance, the EMEA recently stated that "the absence of a structural alert based on a well-performed [software] assessment will be sufficient to conclude that the impurity is of no concern with respect to genotoxicity."http://www.emea.europa.eu/pdfs/human/swp/43199407en.pdf (accessed March 29, 2009).
29. Further draft guidelines have recently been proposed by the FDA: http://www.regulations.gov/fdmspublic/component/main?main)DocumentDetail&o) 09000064807ddb80 (accessed January 27, 2009).
30. Butters, M.; Catterick, D.; Craig, A.; Curzons, A.; Dale, D.; Gillmore, A.; Green, S. P.; Marziano, I.; Sherlock, J.-P.; White, W. Critical Assessment of Pharmaceutical Processes: A Rationale for Changing the Synthetic Route. Chem. Rev. 2006, 106 (7), 3002.
31. Challenger, S.; Dessi, Y.; Fox, D. E.; Hesmondhalgh, L. C.; Pascal, P.; Pettman, A. J.; Smith, J. D. Development of a Scaleable Process for the Synthesis of the A2a Agonist, UK-371,104. Org. Process Res. Dev. 2008, 12, 575.
32. O-Neil, M. J., Ed. The Merck Index, 13th ed.; Merck & Co., Inc.: Whitehouse Station, NJ; 2001; p 431.
33. Wolfenden, R.; Yuan, Y. Monoalkyl sulfates as alkylating agents in water, alkylsulfatase rate enhancements, and the "energy-rich" nature of sulfate half-esters. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 83.
34. Stahl, P. H., Vermuth, C. G., Eds. Handbook of Pharmaceutical Salts: Properties Selection and Use; Wiley-VCH: Zurich; 2002.
35. a-s of group and counterion: Bastin, R. J.; Bowker, M. J.; Slater, B. J. Org. Process Res. Dev. 2000, 4, 427.
36. Chan, L. C.; Cox, B. G.; Sinclair, R. S. Selective Hydrolysis of Methanesulfonate Esters. Org. Process Res. Dev. 2008, 12, 213.
37. Teasdale, A.; Eyley, S. C.; Delaney, E.; Jacq, K.; Taylor-Worth, K.; Lipczynski, A.; Reif, V.; Elder, D. P.; Facchine, K. L.; Golec, S.; Oestrich, R. S.; Sandra, P.; David, F. Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Example for Sulfonate Ester Impurity Formation. Org. Process Res. Dev. 2009, 13, 429.
38. Elder, D. P.; Lipczynski, A. M.; Teasdale, A. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). J. Pharm. Biomed. Anal. 2008, 48, 497.
39. Roth, P.; Leistner, E.; Haverkamp, H. (Hoechst). U.S. Patent 5,843,286
40. No extended drying studies or residual solvent assays were carried out for these batches. All large-scale batches had residual solvent levels well below the ICH guidelines.
41. Temperature cycling of the suspension, as suggested by a reviewer, was not examined as treatment to reduce MeCl in isolated 2 HCl. We thank the reviewer for this suggestion.
42. 2O and MeCl.